We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Polarean Imaging Plc | LSE:POLX | London | Ordinary Share | GB00BF3DT583 | ORD GBP0.00037 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 3.28% | 1.575 | 1.50 | 1.65 | 1.625 | 1.575 | 1.60 | 4,370,476 | 09:01:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Surgical,med Instr,apparatus | 891k | -11.89M | -0.0098 | -1.60 | 18.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
15/11/2024 12:10 | POLX Polarean Imaging about to break out well above 2p soon. Mcap only $20mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.6p and gap at to 3.4p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations. Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR, not advice. | m_night10 | |
15/11/2024 11:28 | Total of $30m to $35m, inclusive of money raised in the anticipated 2024 financing, from investment and strategic deals needed to fund the Company to profitability, investment focused on: Polarean strategic update as above - TWO years since FDA approval - failure to commercialise ONE denovo sale to Alabama and ONE denovo sale to an unnamed !!!! client Directors taking over $1 million cash and nearly the same $1 million cost of options - no cutbacks for von jacko on at least 3/4million cash. 30 staff employed - the most expensive salaries and wages finance department in the USA because few sales invoices. Directors REPRICED their options because the share price fell - same directors Directors allocate themselves over 181 million more options to motivate themselves- not content with million in cash for their fees and salaries Nukem and Bracco and directors with options have taken nearly 50% of the company FAILURE to deliver - Destruction of share price - The stock market doesn't rate them - just look at the graph the directors are looking after themselves Complete refusal to market in partnership into any other jurisdiction including the UK - WHY? | goldbutler | |
15/11/2024 10:42 | Think you need to spam other threads again with your bullet points | moontheloon | |
15/11/2024 10:20 | You waste your time and life moon. A few buys like the 740k you see now and it will go to 2p and then over with news faster than you can blink. :) POLX Polarean Imaging about to break out well above 2p soon. Mcap only $20mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.6p and gap at to 3.4p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations. Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR, not advice. | m_night10 | |
15/11/2024 09:44 | Hopes not deals. Deals hard and fast are required. Closed budget period is the demon here. | moontheloon | |
15/11/2024 09:43 | It the paid for proactive infomercial that got the rampers giddy here and lse. It's a ramp without news. A prolonged period. And an heavy director wage bill. He actually just said the same hopes that cvj did.Philips partnership Been in place a long while, with zero cross selling. Or anything of note. And always worked with ge and seimens but maybe in research capacity. | moontheloon | |
15/11/2024 09:39 | The selling pressure I foretold. Sorry guys. Not news no candy | moontheloon | |
15/11/2024 09:13 | All the pundits on Vox Markets used to bang on about this, I notice Vox has had a bit of a personal cull and Stocko to some degree of recent times. This always was a bargepole, wonder how many mugs these Vox clowns lured in. | owenski | |
15/11/2024 08:27 | And bones pumping is another glaring warning flag. 2p lol without news and no news in 4 months. The 2025 targets is now a massive concern for me. And the short and fast decreasing cash runway. As i said many many times with close budget period within med institutions, if they negotiate any deals then late spring is when the money in budgets might be available. Then as we get past July 2025. The cash runway will be in sharp focus around that time and the share price will be eroded some more ...and then diluted some more.If deal traction continues at this pace. I have a hunch that next rns will be amending fy forecasts due to kits not fully integrated and paid for in current year. | moontheloon | |
15/11/2024 07:57 | I notice this is another 'andrbea' stock, just like TERN, no wonder it's a complete dud. | owenski | |
14/11/2024 16:03 | Down soon or tomorrow with that sell volume. Apologies pump crew | moontheloon | |
14/11/2024 15:21 | Trying to keep the sellers out raise the bed. No one wants to touch this without commercial traction | moontheloon | |
14/11/2024 15:20 | And as if by magic. | moontheloon | |
14/11/2024 13:20 | No news. Nice opportunity to get out . Don't listen to the parasites on here. Especially repeat bullet points .Simply more commercial traction required to avoid another cash call. Unfortunately | moontheloon | |
14/11/2024 12:27 | 200DMA down to 2.6p now, which will act as a magnet for those on the sidelines. I think this will get to 2.1p ahead of news. Then some news from now unitl the end of the year will get it to cross the 200DMA when it is down to the 2.2-2.4p by the times news comes. Once it crosses the 200DMA it acts as a bull flag for it to fill the gap up to 3.2p. If the news is very good, some more Xenon orders, a new partnership, update on 6-12 or gas exchange then I suspect it can even kick on to the 4-5p level quite quickly. I will be adding a final tranche at the end of this month and hope to do this before they move it up. So I wouldn't mind if it sits at at 1.6-1.8p and under 2p for the next 2 weeks. ;) | m_night10 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions